Mass General Brigham, Department of Neurology, Harvard Medical School, Boston, MA, USA.
ATLANTES Research Program, Institute for Culture and Society, University of Navarra, Pamplona, Spain.
Oncologist. 2022 May 6;27(5):e402-e405. doi: 10.1093/oncolo/oyac033.
Immune checkpoint inhibitors (ICIs) have been associated with neurological immune related adverse events (irAE-N) and patients with ICI toxicity may present with neurological or ocular symptoms. Furthermore, patients on ICI may initially present to oncology or neurology. We report a case series of 3 patients treated with ICIs presenting with diplopia or ptosis, found to have concurrent myocarditis in addition to immune-related myopathy (irMyopathy) or myasthenia gravis (irMG). None of the patients described cardiac symptoms, underscoring the importance of screening for myocarditis in patients presenting with diplopia and/or other neuromuscular symptoms which may suggest either irMyopathy or irMG.
免疫检查点抑制剂 (ICIs) 与神经免疫相关不良事件 (irAE-N) 相关,ICI 毒性患者可能出现神经或眼部症状。此外,接受 ICI 治疗的患者最初可能会到肿瘤科或神经科就诊。我们报告了 3 例接受 ICI 治疗的患者出现复视或上睑下垂,除免疫相关性肌病 (irMyopathy) 或重症肌无力 (irMG) 外,还发现同时患有心肌炎。描述的患者均无心脏症状,这强调了在出现复视和/或其他神经肌肉症状的患者中筛查心肌炎的重要性,这些症状可能提示存在 irMyopathy 或 irMG。